The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.
Daiichi Sankyo has partnered with startup AgonOx to develop novel drugs against an undisclosed immuno-oncology target.
Amgen has become the latest big-name drugmaker to strike a deal to access Nuevolution’s discovery platform.
Boehringer has backed out of the $730 million lung cancer pact it struck with Hanmi Pharmaceutical after reviewing the data and competitive landscape.
Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…
Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.
Celgene is paying up under a February 2014 deal with Abide Therapeutics to exercise its option for ex-U.S. rights to its only clinical candidate.
Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.
Johnson & Johnson’s Janssen has licensed two early oncology assets to Tracon Pharmaceuticals through Phase I/II development, then the pharma has the…
Shire has returned rights to the two biosimilars that Baxalta had in development.